Although currently not considered for GBM tumor subtyping, in 50% of cases with EGFR amplifications, tumors also carry a truncated form of EGFR that possesses constitutive kinase activity, which is named EGFRvIII, or otherwise EGFR type III, de2–7, ΔEGFR) [34]. This evidence concerns the gene EGFR and neoplasm.